(Source: Gilead Sciences Inc) - Through Three Years of Treatment, Genvoya Demonstrates Significantly Higher Rates of Virologic Suppression and Favorable Renal and Bone Laboratory Parameters Compared to Stribild- SEATTLE--(BUSINESS WIRE)--Feb. 14, 2017-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced 144-week data from two Phase 3 studies (Studies 104 and 111) evaluating the safety and efficacy of Genvoya (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg) for the treatment of HIV-1 infection in treatment-naïve adults. Through Week 144, Genvoya demonstrated significantly higher rates of virologic suppression compared to Gilead's Stribild...
↧